CRO giant Icon has agreed to trade $143.5 million for Aptiv Solutions, looking to complement its own technology in complex trial design and expand its presence in Japan.
Icon, like most of the world's largest CROs, is investing in high-tech adaptive trial monitoring, and the company's latest offering allows investigators to comb through huge dumps of lab data in real time, tracking trial trends as they happen.
Drugmakers have misfired way more than hit their targets in developing new drugs for complex diseases such as Alzheimer's. Dr. Michael Krams, vice president and head of the neurology franchise at Johnson & Johnson ($JNJ), suggests that part of the problem lies in the way pharma companies have designed clinical trials, according to an article from Bio-IT World.
As clinical trials get more and more complex, Pharmaceutical Product Development has reached out to technology consultancies Tessella and Berry Consultants to use FACTS, adaptive trial software that lets study designers simulate trials in their early planning stages.
As drug developers seek efficient ways to study new treatments for complex disease, Pharmaceutical Product Development has tapped adaptive clinical trials software from technology consultancies Tessella and Berry Consultants.
Aptiv Solutions has grabbed a key piece to the tech puzzle it has been assembling to provide drug and device developers with adaptive clinical trials. The Reston, VA-based CRO, which launched last...
Aptiv Solutions has struck another deal to build its technology offerings in support of complex clinical studies with adaptive designs--also known as adaptive clinical trials. The venture-backed...
Aptiv Solutions is banking on its expertise in areas such as adaptive clinical trials and software development to differentiate the Reston, VA-based CRO. Today, the company outlined its new
Two contract researchers are taking different collaborative approaches to separate from the CRO pack. One has chosen alignment with an adaptive trials specialist; the other, with a trial automation
FDA Commissioner Margaret Hamburg wants to strengthen "a weak link in the chain" between science and drug regulation: the plodding randomized clinical trial. She'd like to see university-based